Crown Bioscience Enters Merger Agreement With JSR Corporation

Shanghai – December 22, 2017 – Cooley advised the special committee of the board of directors of Crown Bioscience International, a global drug discovery and development services, company on its merger agreement with JSR Corporation, headquartered in Tokyo, Japan. The merger is expected to close before the end of second quarter of 2018.

Under the terms of the merger agreement, Crown Bioscience will merge into and become an indirect, wholly-owned subsidiary of JSR and be delisted from the Taipei Exchange. The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in vitro diagnostic solutions, GMP manufacturing capabilities and worldwide distribution networks.

“We are excited to join the JSR family of companies through this innovation-driven strategic partnership,” said Dr. Jean-Pierre Wery, Crown Bioscience’s CEO. “Crown Bioscience’s core competencies in preclinical and translational research combined with JSR’s global footprint, diagnostic solutions and manufacturing capabilities will provide a fully integrated solution to help biopharmaceutical companies get drugs and diagnostics to market more efficiently.”

Crown Bioscience, which trades on the Taipei Exchange under the ticker “6554,” is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.